We should also mention that, whereas our IFN gene therapy also inhibited the growth of the parental ALL, the introduction of a dominant TSA such as OVA might favor an initial cytotoxic response robust enough to allow effective spreading of the immune repertoire to multiple surrogate TSAs and establish durable protection. This evidence concerns the gene IFNA1 and acute lymphoblastic leukemia.